FDA Updates News 17 October 2025

ALT Stock Today (November 25, 2025): Altimmune Extends Rally as Pemvidutide Nears Critical FDA Moment

Key Takeaways ALT stock price today: how Altimmune is trading on November 25, 2025 Altimmune Inc. (NASDAQ: ALT) continues its November rebound. As of early trading on Tuesday, November 25, ALT is changing hands around $5.1 per share, roughly flat

25 November 2025

PSTV Stock on November 25, 2025: FDA Meeting, Nasdaq Extension and Humana Deal Put Plus Therapeutics Back in Focus

As traders log in on Tuesday, November 25, 2025, Plus Therapeutics (NASDAQ:PSTV) is back on the radar thanks to a cluster of late‑November catalysts: an FDA Type B meeting for lead radiotherapeutic REYOBIQ™, a fresh 180‑day Nasdaq bid‑price extension, and

25 November 2025

Biotech Stocks · FDA Updates · Healthcare Deals · Nasdaq Listings · NASDAQ:PSTV · Stock Market News

Scholar Rock (NASDAQ: SRRK) Soars on FDA Progress, $200M ATM and Q3 2025 Earnings – November 14, 2025 Update

Scholar Rock Holding Corporation (NASDAQ: SRRK) is back in the spotlight as its stock jumps more than 25% on the day after a pivotal FDA meeting, fresh Q3 2025 financial results, and the launch of a new $200 million at-the-market

14 November 2025

Biotechnology · Earnings Reports · FDA Updates · NASDAQ:SRRK · NYSE:NVO · Pharmaceutical Industry · Stock Market

Tenaya Therapeutics (TNYA) on Nov. 8, 2025: FDA Places Clinical Hold on TN‑201 Trial as AHA 2025 Showcases Encouraging MyPEAK‑1 Data

What happened today (Nov. 8) Tenaya Therapeutics (NASDAQ: TNYA) presented new interim results from its MyPEAK‑1 Phase 1b/2a trial evaluating TN‑201, an AAV9 gene‑replacement therapy designed to deliver a working MYBPC3 gene to cardiomyocytes for MYBPC3‑associated hypertrophic cardiomyopathy (HCM). The

8 November 2025

Biotech · Clinical Trials · FDA Updates · Gene Therapy · Medical News · NASDAQ:TNYA

Biohaven Stock’s Wild Ride: Big Drops, Big Hopes as FDA Verdict Nears

In summary, Biohaven’s stock is a tale of high stakes in biotech. Recent price swings underscore the uncertainty, but also the potential reward if Biohaven’s bets pay off. With an FDA verdict looming and multiple shots on goal in its

3 November 2025

Biotech News · FDA Updates · Financial Analysis · Investment Strategies · NYSE:BHVN · Stock Market

Salmonella Scare: FDA Upgrades Egg Recall to ‘Highest Risk’ — Are Your Eggs Affected?

Egg supplies and prices remain the backdrop to this story. 163 million U.S. poultry have died from avian flu since 2022, cutting the egg-laying flock by ~11% vs. 2019 reuters.com. Consumers have seen sticker shock – in some cities eggs

22 October 2025

FDA Updates · Food Safety · Health News · NASDAQ:CALM · Product Recalls · Public Health

Femasys (FEMY) Rockets on Fertility Breakthroughs and FDA Milestones – What’s Behind the Surge?

FEMY Stock Soars on Fertility Buzz Femasys stock has been on a rollercoaster ride in recent sessions. As of October 17, 2025, FEMY traded around the mid-$0.70s per share – more than double its price just a few weeks prior,

17 October 2025

Biotechnology · FDA Updates · Fertility · Medical Innovations · NASDAQ:FEMY · Stock Market

FDA Updates News 17 October 2025 - 25 November 2025